Contact

Rootline Home About Services Clinical Evidence Safety & Screening Access & Legal Status Contact Evidence, uncertainty & safety Ibogaine For PTSD Ibogaine is an experimental psychoactive alkaloid being studied for PTSD, especially in veterans with treatment-resistant PTSD and traumatic brain injury. The early signal is striking. The evidence is still small, safety-sensitive, and not sufficient for routine clinical use. 01 What the question actually means Ibogaine is an indole alkaloid extracted from the root bark of Tabernanthe iboga , a shrub native to Central and West Africa. The ibogaine reference overview describes it as a psychoactive substance with a complex and consequential history. 30 Special operations veterans Thirty veterans were treated in a Stanford-led study published in Nature Medicine . 88% Average PTSD reduction Average PTSD symptom reduction was reported at one month in that small cohort. 1 mo. Near-term window One month was the primary near-term follow-up window, making longer-term durability an open question. The evidence signal Large early effects deserve careful reading. The strongest human evidence so far is a small Stanford-led study in special operations veterans showing rapid symptom reduction. The Stanford summary of the veterans study reported an 88% average reduction in PTSD symptoms, alongside reported reductions in depression and anxiety symptoms at one month. Rapid does not mean settled The reported rapidity of change is unusual for psychiatry. It is also why questions about sample size, study design, follow-up, and replication matter so much. PTSD is not isolated here The discussion often overlaps with traumatic brain injury, depression, suicidality, neuroplasticity, opioid-use disorder, and cardiac safety. For background on adjacent uses, ibogaine treatment for addiction is part of the broader context. Experimental status remains central In the United States, ibogaine is not FDA-approved for any condition and remains Sch

Keep the record clear.